Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells 128,127 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the completion of the sale, the chief executive officer now owns 173,655 shares of the company's stock, valued at $5,900,796.90. The trade was a 42.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, February 18th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29.
• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.22, for a total value of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.08, for a total value of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded up $1.83 on Friday, hitting $34.70. The stock had a trading volume of 14,141,140 shares, compared to its average volume of 13,653,104. The firm's 50 day moving average price is $39.02 and its 200-day moving average price is $28.55. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The company has a market capitalization of $7.71 billion, a price-to-earnings ratio of 78.69 and a beta of 1.37.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Farallon Capital Management LLC boosted its stake in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after buying an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. grew its holdings in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the last quarter. Yong Rong HK Asset Management Ltd acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $41,104,000. Finally, Renaissance Technologies LLC increased its position in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after acquiring an additional 1,562,302 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of research reports. Citigroup reissued a "sell" rating and issued a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Morgan Stanley lowered Hims & Hers Health from an "overweight" rating to an "equal weight" rating and boosted their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Finally, Leerink Partners boosted their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $37.31.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.